(Total Views: 271)
Posted On: 07/10/2019 2:42:16 PM
Post# of 154975
I didn't realize this was industry standard, so thanks for enlightening me. I guess they view all drug candidates the same simply based on respective phase, which seems crazy to me, especially given the large variance in safety and efficacy.....which Leronlimab has both.
Regardless how or what the 80% is based on, this will have a positive impact on their evaluation model once approved.
Regardless how or what the 80% is based on, this will have a positive impact on their evaluation model once approved.
(0)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
